Read in isolation, the Lunch Talks look like twelve topics in a programme. Read together — and as Thilo Buck & Kees Mensch set out in the year-one wrap-up on 21 May — they tell a single story: the structural shift from documents to data as the unit of truth in pharma. The series continues.
In the year-one wrap-up, Thilo Buck and Kees Mensch reframe the series under a tighter lens — three themes that move from the foundations of digital manufacturing, through its operational reality, to the human and organizational shift that makes it real. Two cross-cutting strands run underneath.
Digitalisation is not software implementation. Data flows matter more than isolated systems. Manufacturing is itself an information system, and process understanding requires visibility.
Governance, workflows, review-by-exception, continuous process verification, lifecycle validation, organisational redesign — where the shift meets the operating day.
Workforce readiness, culture, change management, organisational maturity, cross-functional collaboration. The discipline most resistant to data-as-truth thinking — and therefore the one needing the most community attention.
Each node is a Lunch Talk, sized and coloured by the dominant theme that surfaced afterwards. The gap is the summer break; the navy node marks the year-one wrap-up on 21 May — the series continues.
Pharma 4.0 is the industry's shift from documents as the unit of truth to data as the unit of truth — and every discipline in the operating model is being reorganised around that shift.
The central thesis · reconstructed from twelve sessions
Each session maps onto a face of the central thesis. The coloured rail indicates the dominant theme it raised; the year-one wrap-up — Thilo & Kees on 21 May — pulls all of it back together. The series continues.
The dependencies between regulators, suppliers and manufacturers, and the importance of standards. The value of a pilot environment that produces sustainable, not theatrical, results.
Most people over-focus on systems. Data outlives processes and systems — and treating it that way changes how a transformation is sequenced.
Why an integral approach to Pharma 4.0 matters, and the value generated when the four operating-model disciplines stay in balance rather than compete.
Restructuring the HR function: broader job descriptions, shifting specialist roles, a leaner HR digital backbone, and a move from roles to skills.
A process on paper is not the same as a digital process SOP. Work instructions can be cleanly split by actor — less work for QA, more relevance for operators, no one-size-fits-all.
The role of MTP files as a connectivity layer — effectively an API for production equipment — and the implications for changeover times and overall industry readiness.
Centred on data architecture and the auditing of data as a discipline in itself. Conceptually strong; the practical playbook is still being written.
The Pharma 4.0 journey through the lens of digital maturity: skills development, large-scale implementation, and what a credible learning path looks like.
Using data — process data especially — as the primary evidence for the validated state, rather than as a downstream artefact of it.
A concrete example of dismantling redundant paper records and multiple-entry workflows — and what changes operationally when you do.
Integration of information across the quality function, and the persistent challenge of islands of information that the industry has yet to fully bridge.
The year-one wrap-up delivered: a working definition of holistic digital manufacturing maturity, the chairs' three-theme reframing, five live audience polls (29 respondents), six provocations that exposed where the community quietly disagrees with itself, and a clear forward agenda for the year ahead. Scroll down for the full poll results.
The argument is only as good as the people who carried it. Below is each speaker's current role, their ISPE involvement, and the single observation they brought to the series. Researched from public ISPE biographies and company sources.
" The degree to which an organization can reliably use integrated data, digital systems, and operational intelligence to enable scalable, adaptive, and continuously improving manufacturing processes — across facilities and across people.
The working test: can a company explain why something happened, in near real time?
Audit-ready, not merely compliant.
Five live polls and a word cloud — 29 participants responded in real time. Together they confirm the chairs' synthesis, surface the community's anxieties, and name what comes next.
The polls told us the numbers. The open microphone told us the thinking behind them. These are the sharpest observations from the live discussion — unscripted, from the floor.
The biggest challenge is not bringing all the data together, but then having the conversations internally — what does that data mean to you as a company as a whole?
We have to really have use cases and beneficiary points of the people that use the data. Once you get the people that use the data daily on board, shifting the culture in the company is quite easy.
A lot of the data that's out there is mostly software information and very, very sale marketing language. I attend amazing webinars like this to try and gather information that is neutral — to balance out what is really going on in the industry.
Paper on glass — you take your form and make it digital, but you use exactly the same fields, exactly the same steps, exactly the same signature activities. And that slows down the benefits the systems can bring.
Your digital solution should enable a company and not restrict you. On the other hand — if you don't fit in the system, the system often follows leading best practices. You should also start wondering whether your process is maybe not efficient.
Instead of creating an environment that is already fire retardant, they just focus on the fires. There is always something that is more important than doing this.
Accept that when you start those pilots, roles are not so clear and responsibilities are not so clear — and that's just part of the process.
Statements the chairs put to the room on 21 May — not conclusions, but prompts engineered to expose where the community quietly disagrees with itself.
Most Pharma 4.0 programmes fail because of culture, not technology.
Digital control strategies rarely rely on scale-independent parameters.
Many companies digitalize inefficient processes instead of redesigning them.
Validation 4.0 will eventually reduce QA headcount.
The future QA professional needs systems thinking more than documentation skills.
ATMPs will force the industry to adopt platform-based manufacturing.
Beneath the chairs' three-theme overview sits a finer-grained synthesis: across fifteen months, the same handful of ideas kept returning, in different vocabularies, from different speakers, at different layers of the operating model.
The year-one wrap-up ended with the community itself naming the gaps. Six topic areas are being put forward as candidates for the autumn programme and beyond — each is a place where the central thesis still has work to do.
At Adryan
Adryan is a leading life sciences consultancy with offices in the Netherlands and Switzerland, active throughout Western Europe. We provide a full range of services to the (bio-)pharmaceutical and high-end food industries, with expertise in Project Management, Technical Services & Operations, CQV, and Compliance.
Why Adryan sponsors this series
150+ engineers & consultants · Netherlands & Switzerland
Through our sponsorship of the ISPE Pharma 4.0™ Lunch Talk Series, Adryan reinforces its commitment to advancing digital transformation in the life sciences industry. By supporting this initiative, we contribute to an open exchange of knowledge, best practices, and insights that drive innovation in pharmaceutical manufacturing.
150+
Engineers &
Consultants
4
Offices across
Western Europe
20+
Years of
experience
2×
Exclusive series
sponsor
What we do
CQV
Strategic flagship
Commissioning, Qualification & Validation across the full regulated lifecycle.
Compliance
GxP & Regulatory
GxP compliance throughout the pharmaceutical and biotech lifecycle.
Project Management
End-to-end delivery
End-to-end project leadership for complex pharma and biotech projects.
Technical Services
Operations & Engineering
Engineering and operational support across Western Europe.
Netherlands — Head Office
Adryan B.V.
Wilgenbos 2, 3311 JX Dordrecht
+31 78 204 00 34
info.nl@adryan.com
Netherlands — Leiden
Adryan B.V.
Emmy Noetherweg 2
2333 BK Leiden
info.nl@adryan.com
Switzerland
Adryan AG
Aeschengraben 29
CH-4051 Basel
+41 27 552 00 34
info.ch@adryan.com
© Adryan · adryan.com
ISPE NL Pharma 4.0™ Exclusive Series Sponsor
Twelve months in — and the audience has already named the next priorities. Data governance leads, AI governance is close behind, and the room wants to meet in person. Stay connected to shape the programme ahead.
